ASCO 2015 Highlights

Value Assessments of Metastatic Colorectal Cancer Therapies Continue to Focus on Cost

By Charles Bankhead

Value in Oncology

October 2016, Vol 7, No 9

Patient-Reported Outcomes Should Be Used Routinely in Cancer Care

Palliative Care, Personalized Medicine

October 2016, Vol 7, No 9

Death Rates Unaffected by Treatment Choice for Patients with Localized Prostate Cancer

By Alice Goodman

Prostate Cancer, Solid Tumors

October 2016, Vol 7, No 9

No Clear Selection Criteria for Genomic Testing in Patients with Metastatic Colorectal Cancer

By Charles Bankhead

Colorectal Cancer, Solid Tumors

October 2016, Vol 7, No 9

Many Cancer Survivors Have Untreated Depression

By Charles Bankhead

Survivorship, Policies & Guidelines

October 2016, Vol 7, No 9

New Genetic Test May Give Early Warning of Aggressive Prostate Cancers

By Charles Bankhead

Genetic Testing, Personalized Medicine

October 2016, Vol 7, No 9

New Anticancer Drugs Increase Costs but Prolong Life

By Laura Morgan

Value in Oncology

October 2016, Vol 7, No 9

A study by David H. Howard, PhD, Associate Professor, Department of Health Policy and Management, Emory University, Atlanta, and colleagues demonstrated that although anticancer drugs are associated with increased expenses, they were also accompanied by considerable survival benefits across different cancer types (Howard DH, et al. Health Aff [Millwood]. 2016;35:1581-1587)

Immunotherapies Changing the Treatment Landscape of Advanced Cancer Care

Immunotherapy, Personalized Medicine

October 2016, Vol 7, No 9

Precision Medicine Initiative Cohort Program Ushers in a New Era in Medicine

By Jessica Miller

Personalized Medicine

October 2016, Vol 7, No 9

Number of Cancers Convincingly Linked to Obesity More Than Doubles

By Charles Bankhead

Cancer Prevention, Personalized Medicine

October 2016, Vol 7, No 9

Page 148 of 330